First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children
First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children News provided by Share this article Share this article STOCKHOLM, March 12, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist (TPO-RA), for treatment of immune thrombocytopenia (ITP) in pediatric patients. This phase 3 study, the first the evaluate avatrombopag in children, will evaluate efficacy, safety, and pharmacokinetics of avatrombopag in the treatment of pediatric s...
Source: prnewswire.com